Xavier Duportet is a genome architect. He cofounded Eligo Bioscience in 2014, while doing his PhD in Synthetic Biology at MIT and INRIA. He raised over €3M to develop a new generation of ultra-precise biotherapeutics to battle antibiotic-resistant bacteria and sculpt our microbiome using genetic engineering. He is an MIT TR35, Forbes 30 Under 30 and was elected French Innovator of the year by the MIT Technology Review. He was recently awarded French PhD-Entrepreneur of the year by the Foundation Norbert Segard, as one of the 40 under 40 Young Leaders in Europe, and French Young Leader by the Leadership Circle. Xavier is also the founder and president of Hello Tomorrow, a global non-profit organization, operating in 45 countries, which goal is to accelerate the development of deeptech startups that transform disruptive scientific technologies into products or services to solve societal and industrial challenges. He has already raised more than $6M for this cause. Every year, the organisation receives more than 5000 startup applications from the best research centers worldwide, gathers more than 1000 deeptech founders via more than 100 events with iconic leaders such as Michael Bloomberg, CEO of Deepmind, CTO at NASA, CEO at Unity Biotech, Emmanuel Macron and many others, and distributes more than $1M in prizes to the most promising early-stage science startups.